A case of ovarian psammocarcinoma with homolateral serous cystoadenofibroma and thecoma associated with Brenner tumour and cystoadenofibroma of the contralateral ovary

Psammocarcinoma of the ovary is a rare serous neoplasm, with only 32 cases reported in the international literature. Characteristically, this tumour shows extensive formation ofpsammoma bodies, low-grade cytological features, and invasion of the ovarian stroma, peritoneum or intraperitoneal viscera. The behaviour of this entity is unpredictable, with benign, low malignant and metastatic potential. Herein the authors report a case ofpsammocarcinoma of the ovary with homolateral serous cystoadenofibroma and thecoma, which were associated with Brenner tumour and adenofibroma of the contralateral ovary, in a 78-year-old woman. Thus, this example shows an unpredictable tumour associated with multiple benign epithelial neoplasms and a benign stromal tumour. Moreover, this example of psammocarcinoma is very interesting because it measures only 1.5 x 0.5 x 1.5 cm and, to the best of the author's knowledge, represents the smallest case ofpsammocarcinoma described so far in the literature

Primary alveolar soft part sarcoma of uterine corpus: a case report with immunohistochemical, ultrastructural study and review of literature

Background Alveolar soft part sarcoma (ASPS) is a rare mesenchymal malignancy. ASPS usually occurs most commonly in the deep soft tissues of the thigh and buttock or the head and neck regions. ASPS that originate from the uterine corpus are even more rare, with only 10 previous cases reported in the English literature. Case presentation In our case, the alveolar features were completely lost and the tumour shows a solid, non-alveolar pattern and the nuclei have marked variation in nuclear size, and multinucleation. The correct pathological diagnosis has been made by immuno- histochemical and ultrastructural features, which rvealed overexpression of TFE3 and peculiar cytoplasmic crystalline inclusions. In this paper, an additional case of primary ASPS of uterine corpus is reported with immunohistochemical, ultrastructural study and review of literature in the effort to delineate its clinical and pathological features. In this unusual site, the diagnosis can be problematic because ASPS can mimic other primary or metastatic uterine neoplasms. Conclusions Thus, in this unusual presentation an essential diagnostic marker is the nuclear over-expression of TFE3 as well as ultrastructural study, which reveals the presence of peculiar cytoplasmic crystalline inclusions

CD99 Expression and Prognostic Impact in Glioblastoma: A Single-Center Cohort Study

Glioblastoma is the most frequent and aggressive brain tumor in adults. This study aims to evaluate the expression and prognostic impact of CD99, a membrane glycoprotein involved in cellular migration and invasion. In a cohort of patients with glioblastoma treated with surgery, radiotherapy and temozolomide, we retrospectively analyzed tumor expression of CD99 by immunohistochemistry (IHC) and by quantitative real-time polymerase chain reaction (qRT-PCR) for both the wild type (CD99wt) and the truncated (CD99sh) isoforms. The impact on overall survival (OS) was assessed with the Kaplan-Meier method and log-rank test and by multivariable Cox regression. Forty-six patients with glioblastoma entered this study. Immunohistochemical expression of CD99 was present in 83%. Only the CD99wt isoform was detected by qRT-PCR and was significantly correlated with CD99 expression evaluated by IHC (rho = 0.309, p = 0.037). CD99 expression was not associated with OS, regardless of the assessment methodology used (p = 0.61 for qRT-PCR and p = 0.73 for IHC). In an exploratory analysis of The Cancer Genome Atlas, casuistry of glioblastomas CD99 expression was not associated with OS nor with progression-free survival. This study confirms a high expression of CD99 in glioblastoma but does not show any significant impact on survival. Further preclinical studies are needed to define its role as a therapeutic target in glioblastoma

Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity

Aim: In renal cell carcinoma (RCC), tumor heterogeneity generated challenges to biomarker development and therapeutic management, often becoming responsible for primary and acquired drug resistance. This study aimed to assess the inter-tumoral, intra-tumoral, and intra-lesional heterogeneity of known druggable targets in metastatic RCC (mRCC). Methods: The RIVELATOR study was a monocenter retrospective analysis of biological samples from 25 cases of primary RCC and their paired pulmonary metastases. The biomarkers analyzed included MET, mTOR, PD-1/PD-L1 pathways and the immune context. Results: High multi-level heterogeneity was demonstrated. MET was the most reliable biomarker, with the lowest intratumor heterogeneity: the positive mutual correlation between MET expression in primary tumors and their metastases had a significantly proportional intensity (P = 0.038). The intratumor heterogeneity grade was significantly higher for the mTOR pathway proteins. Combined immunophenotypical expression patterns and their correlations with the immune context were uncovered [i.e., mTOR expression in the metastases positively correlated with PD-L1 expression in tumor-infiltrating lymphocytes (TILs), P = 0.019; MET expression was related to PD-1 expression on TILs (P = 0.041, ρ = 0.41) and peritumoral lymphocytes (RILs; P = 0.013, ρ = 0.49)], suggesting the possibility of predicting drug response or resistance to tyrosine kinase, mTOR, or immune checkpoint inhibitors. Conclusions: In mRCC, multiple and multi-level assays of potentially predictive biomarkers are needed for their reliable translation into clinical practice. The easy-to-use immunohistochemical method of the present study allowed the identification of different combined expression patterns, providing cues for planning the management of systemic treatment combinations and sequences in an mRCC patient population. The quantitative heterogeneity of the investigated biomarkers suggests that multiple intralesional assays are needed to consider the assessment reliable for clinical considerations

Immunohistochemical expression of Napsin A in normal human foetal lungs and congenital and acquired pathologic conditions

Background&Objective: Surfactant protein B (SP-B) is a key component of pulmonary surfactant. SP-B is processed to mature surface-active protein from a pro-peptide by two distinct cleavages at its N-terminal and C-terminal portions. Napsin A is the protease, expressed in type-II pneumocytes, involved in the N-terminal cleavage of this pro-peptide. In this paper, for the first time, we evaluate the immunohistochemical expression of Napsin A in normal human fetal lungs at different gestational ages, and in examples of congenital and acquired pulmonary pathological conditions. Method: Samples of lungs were collected at the Department ofMedicine and Surgery of Parma University, (Italy) from fetal and neonatal autopsies. The immunohistochemical study was performed using primary monoclonal antibody anti-Napsin A (clone MRQ-60). A section of lung adenocarcinoma was used as an external positive control. Results: The results reveal that Napsin A is expressed early in normal fetal lungs and in the entire epitheliumof distal pseudoglandular tracts. At 30 weeks’ gestation and in the newborn at term of pregnancy, immunoreactivity to Napsin A already presents the same distribution as that in adult subjects, affecting isolated cells of the alveolar epithelium. In pathological conditions, such as inflammatory diseases and pulmonary hypoplasia, both in the fetus and in the newborn, this study demonstrates an increase in the expression of Napsin A compared to a control group. Conclusion: In conclusion, this study demonstrates that Napsin A is produced early during fetal life and its production increases in many diseases in the effort to resolve a functional pulmonary deficiency

Pityriasis lichenoides getriggert durch eine Masern‐Mumps‐Röteln‐Impfung

n.a

Pigmented purpuric dermatoses: analysis of epidemiological, clinical and histopathological aspects in relation to the prognosis of 70 patients, including infants and adults

Pigmented purpuric dermatoses (PPDs) are a group of chronic-relapsing, inflammatory purpuras without vasculitis that typically involve the lower limbs. Five major types could be distinguished, according to the clinical and histopathologic analysis. The etiopathogenesis is still unknown and multiple factors have been considered. Prognosis seems not to be influenced by the different clinical forms of PPDs; nevertheless no previous studies have investigated whether it could be influenced by the anatomical distribution of the disease

Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma

Aim: The knowledge of the immune context of renal cell carcinoma (RCC) is useful to predict benefit from immunotherapy. We retrospectively characterized the immune context of RCC patients underwent primary nephrectomy and pulmonary metastasectomy. Materials & methods: Intratumoral infiltrating lymphocytes and peritumoral renal infiltrating lymphocytes, lymphocyte subpopulations (CD4+, CD8+), PD-1, PD-L1 were explored in paired samples of primary RCC (T) and respective pulmonary metastases (M). Results: The immune variables demonstrated intralesional and intratumoral heterogeneity. Intralesional lymphocyte heterogeneity reached 76% of cases in T, 28% in M. The heterogeneity rate for PD-L1 expression was from 44% (T) to 56% (M); it correlated with better survival. Conclusion: The immune context of RCC is highly variable both within a given tumor and among primary and metastases